Fosun Pharmaceuticals rose in dry and port markets, with A-shares and Hong Kong stocks rising by nearly 4% and nearly 6% respectively. Earlier, the company announced that the subsidiary signed a licensing agreement with Pfizer for the GLP-1R agonist, which could receive up to 500 million US dollars.

Fosun Pharmaceuticals rose in dry and port markets, with A-shares and Hong Kong stocks rising by nearly 4% and nearly 6% respectively. Earlier, the company announced that the subsidiary signed a licensing agreement with Pfizer for the GLP-1R agonist, which could receive up to 500 million US dollars.